Digital vertigo therapy: efficacy results of the confirmatory randomized controlled multicenter GEVE II trial

For millions of people, the world spins when it should be still. This sensation, known as vertigo, is not merely a momentary dizziness but a profound disruption of balance that can make walking, reading, or even standing up feel like navigating a ship in a storm. While the inner ear acts as the body's built-in gyroscope, detecting movement and orientation, this system can fail due to infection, aging, or injury. When the inner ear sends faulty signals to the brain, the result is a chronic condition that severely limits daily life. For decades, doctors have faced a frustrating reality: while there are drugs to calm the acute nausea of a sudden attack, there is no proven medication that fixes the underlying problem of chronic dizziness. The standard approach has been physical therapy, where patients perform specific head and eye movements to help the brain relearn how to interpret balance signals, a process known as central vestibular compensation. However, the effectiveness of these traditional methods varies, and the need for a more reliable, accessible solution has grown.

A recent large-scale study has now tested a new approach that moves this rehabilitation from the clinic to the living room. Researchers conducted a rigorous, multi-center trial involving 259 patients suffering from chronic peripheral vertigo, a condition where the balance system in the inner ear is damaged. The study compared two groups: one receiving standard physical therapy guided by a therapist, and the other using a digital therapeutic program called VH90D. This program is a CE-marked medical device that runs on smartphones and tablets, delivering a structured, 90-day regimen of sensorimotor and visual exercises. The goal was to see if this digital tool could induce the brain's natural ability to compensate for the inner ear's failure more effectively than traditional care. The results were striking. The group using the digital program saw their vertigo symptoms drop by an average of 65 percent, a reduction far greater than the 23 percent improvement seen in the group receiving standard physical therapy.

The study, known as the GEVE II trial, was designed to be a definitive test of this technology. It was a randomized, controlled trial, meaning patients were assigned by chance to either the digital treatment or the standard care group, ensuring a fair comparison. The participants, ranging in age from young adults to the elderly, suffered from a variety of inner ear disorders, including vestibular migraines, nerve damage, and age-related balance decline. Over the course of twelve weeks, the researchers measured how much the patients' symptoms improved using a validated scale that tracks the intensity of dizziness and its impact on daily life. The digital group, which used the app for about ten to twenty-five minutes a day, showed a dramatic decrease in symptom severity. Their scores on the vertigo scale fell by roughly twelve points on a scale of thirty-two, a change that was both statistically significant and clinically meaningful. In contrast, the group receiving standard physical therapy saw a much smaller improvement, with their scores dropping by only about three and a half points.

Beyond just the feeling of spinning, the study also looked at how the treatment affected the patients' quality of life. Using a questionnaire that measures the handicap caused by dizziness, the researchers found that the digital group experienced a nearly forty percent reduction in their daily limitations, compared to an eighteen percent reduction in the control group. This suggests that the digital therapy did not just make the spinning stop; it helped people regain their ability to function in the world. The researchers noted that the digital program worked by providing consistent, repetitive visual and movement stimuli that encouraged the brain to reorganize its processing of balance signals. This process, which relies on the brain's plasticity, was triggered more effectively by the structured, daily engagement of the app than by the less frequent sessions of traditional therapy.

Safety was also a key focus of the investigation. The researchers monitored the participants closely for any adverse reactions. No serious side effects were observed in the digital group. The few minor issues that arose were temporary and manageable, occurring at a rate similar to that of the physical therapy group. This indicates that the digital intervention is a safe option for patients who might otherwise struggle with the demands of in-person therapy or who have no other effective treatment options. The study authors emphasized that while the results are highly promising, the trial was limited to a twelve-week period, so the long-term persistence of these benefits will need to be confirmed by future research. Additionally, the study population included a wide mix of diagnoses, which strengthens the general applicability of the findings but means that specific subgroups were not analyzed in isolation.

The implications of these findings are significant for the field of neurology and otology. For years, the medical community has lacked a high-quality, evidence-based treatment for chronic peripheral vertigo that goes beyond temporary symptom relief. This study provides strong proof that a digital therapeutic can fill that gap, offering a scalable, non-invasive solution that patients can use at home. The success of the VH90D program suggests that the future of vestibular rehabilitation may lie in the integration of technology with established medical principles. By harnessing the brain's ability to adapt through structured digital exercises, clinicians can offer a treatment that is not only effective but also accessible to a broader population. The study concludes that this digital approach represents a major step forward, providing a significant clinical benefit for patients who have long suffered from the debilitating effects of chronic dizziness.